Abstract
The encapsulation of therapeutic agents into nano-based drug delivery system for cancer treatment has received considerable attention in recent years. Advancements in nanotechnology provide an opportunity for efficient delivery of anticancer drugs. The unique properties of nanoparticles not only allow cancer-specific drug delivery by inherent passive targeting phenomena and adopting active targeting strategies, but also improve the pharmacokinetics and bioavailability of the loaded drugs, leading to enhanced therapeutic efficacy and safety compared to conventional treatment modalities. Small molecule drugs are the most widely used anticancer agents at present, while biological macromolecules, such as therapeutic antibodies, peptides and genes, have gained increasing attention. Therefore, this review focuses on the recent achievements of novel nano-encapsulation in targeted drug delivery. A comprehensive introduction of intelligent delivery strategies based on various nanocarriers to encapsulate small molecule chemotherapeutic drugs and biological macromolecule drugs in cancer treatment will also be highlighted.
Highlights
Nanomedicine holds the advantages of passive targeting abilume ratio for drug loading, a tunable size for modification, a prolonged plasma half ity due to an enhanced permeability and retention (EPR) effect, a large surface-to-volume and a different biodistribution profile compared to conventional chemotherapy ratio for drug loading, a tunable size for modification, a prolonged plasma half-life and a couragingly, several chemotherapeutics-related nano-based formulations have been different biodistribution profile compared to conventional chemotherapy [7]
The cytotoxicity test toward PC-3 cells demonstrated that reconstituted high-density lipoprotein (rHDL)-superparamagnetic iron oxide nanoparticle (SPION)-valrubicin NPs were up to 4.6 and 31 times more effective at the respective valrubicin concentrations of 42.4 μg/mL and 85 μg/mL than valrubicin alone, implying that rHDL-based targeted drug delivery through magnetic navigation could effectively enhance the therapeutic efficacy of prostate cancer treatment
BxPC-3 cells were used to test the tumor penetration ability of this drug delivery system (DDS) in vitro, and the results revealed that the DDS had ideal tumor penetration ability, which occurred via the GGT-activated cationization and was dependent on the caveolae-associated internalization and efflux process
Summary
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Nanomedicine holds the advantages of passive targeting abilume ratio for drug loading, a tunable size for modification, a prolonged plasma half ity due to an enhanced permeability and retention (EPR) effect, a large surface-to-volume and a different biodistribution profile compared to conventional chemotherapy [7]. Ratio for drug loading, a tunable size for modification, a prolonged plasma half-life and a couragingly, several chemotherapeutics-related nano-based formulations have been different biodistribution profile compared to conventional chemotherapy [7]. This review focuses on the application of nanotechnology in ogy in cancer therapy and discusses how these nanoparticles (NPs) encapsulate the t cancer therapy and discusses how these nanoparticles (NPs) encapsulate the therapeutic apeutic agents in targeted drug delivery (Figure 1). Induce immunogenic cell death, and enhance antitumor efficacy of about 71% tumor growth inhibition rate [34]. Increase the sensitivity of HCC cells and enhance the antitumor efficacy of sorafenib [41]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
